QIAGEN N.V. to Report Fourth Quarter and Full-Year2013 Results and Hold Webcast
VENLO, The Netherlands, January 13, 2014 – QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) today reconfirmed plans to release its report on results for the fourth quarter and full-year of 2013 on Wednesday, January 29, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET).
Also as previously announced, a conference call is planned for Thursday, January 30, at 15:30 CET / 9:30 ET that will include remarks by Peer M. Schatz, President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
Conference Call & Webcast Details
The conference call will begin at 15:30 CET / 9:30 ET on January 30, 2014. Interested parties may listen to the call by dialing:
+1 855 272 3518 (US), +44 (0) 203 059 5869 (UK), +49 (0) 69 566 036 000 (Germany)
The webcast will be accessible at www.qiagen.com/About-Us/Investors/Events-and-Presentations/Conference-Calls.
A replay of the conference call will be available through February 6, 2014, by dialing:
+1 866 268 1947 (US), +44 (0) 121 260 4861, +49 (0) 69 710 488 70 (passcode: 802495#).
QIAGEN N.V. is a Netherlands holding company publically traded on NASDAQ and Frankfurt Prime Standard. The Company is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular insights. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2013, QIAGEN employed more than 4,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.